Why the global slowdown in production of the corona vaccine? – One world – out of bounds


While the numbers of people living with and infected with Coronavirus are increasing alarmingly around the world, the global effort to find an effective vaccine for the virus is still little and has not reached tangible results.

Doctors try tests for antivirals to find out how they can affect the Corona virus.

Work is accelerating in this type of experiment and research, and good news comes about the vaccine and treatment of the emerging virus from Germany and France, and an experimental attempt in America and other vaccines in Russia, but the effective vaccine does not exist yet.

The major pharmaceutical companies have not yet received their weight in the process of developing a new vaccine for the new Coronavirus, because they still do not have sufficient guarantees to make any significant profits if they decide to go out this way and spend billions of dollars of their money in that endeavor.

And a number of specialists confirm that companies fear that the fate of “Corona” will be like “SARS”. About 17 years ago, there were companies that started developing vaccines for SARS, but when the time came to conduct clinical trials there were no more patients because the virus was gone.

All the trials that have been conducted regarding a vaccine to tackle Corona have not reached any final results, as all possibilities are being tried to find solutions to confront the virus.

But without spending a lot of money, because that is not guaranteed if the epidemic recedes gradually without relying on the vaccine.

The World Health Organization confirmed that it needed hundreds of millions of dollars to test several vaccines against Corona, requiring government sectors to participate in funding vaccination tests against the disease.

The search for a vaccine – which many experts believe will emerge after at least 12 to 18 months – is central to global efforts to restart economies.

But, just like the swine flu, this process raises questions about whether countries will move in the narrow straits of their own interests, or embrace a more cooperative, global approach.

There are over 100 potential vaccines currently in the testing phase, and we will need tremendous efforts that cost tens of billions of dollars.

Mark Feinberg, the former scientific director of Merck Vakings and the current president of the International AIDS Vaccine Initiative, notes that laboratories have learned the lesson and will not want to turn to a “pariah” party in the equation, which could harm its reputation and ability to make profits.

Weinberg believes that sharing intellectual property will inevitably take place, because “nobody can alone respond to global demand, and it will force any party to search for partners to make the product.”



Please enter your comment!
Please enter your name here